Table 1

Patient characteristics

Timing of CNS-HL diagnosis*SexYear of CNS-HL DiagnosisAge at CNS-HL diagnosis, yType of HLStage at first HL diagnosisStage at CNS-HL diagnosisConfirmation of CNS-HL diagnosisChemotherapy for CNS-HLRadiation for CNS-HL (dose)Response to first-line CNS treatmentStatus at last follow-up (survival since HL diagnosis)
1 Primary‡ F 2000 58 CHL NOS IE IE Resection None WBRT (35 Gy) CR Alive (90.3+ mo) in CR 
2 Primary‡ F 2008 60 NS IE IE Resection None WBRT (to begin) NA Alive (1+ mo) 
3 Initial§ M 2004 46 CHL NOS IE IE Biopsy Unknown Unknown Unknown Alive (2.1+ mo) 
4 Initial†§ M 2007 72 CHL NOS IE IE Resection None (surgery alone) None (surgery alone) NA Alive (5.4+ mo) in CR 
5 Initial§ F 1980 37 MC IE IE B Biopsy MVPP WBRT PR Dead from systemic PD (15.5 mo) 
6 Initial† M 1997 19 NS IV IV Biopsy Stamford V + PBSCT + it MTX PBRT (36 Gy) CR Alive (128.5+ mo) in CR 
7 Initial† M 2007 44 CHL NOS IV IV CSF ABVD Radiosurgery PR Dead from CNS PD (4.5 mo) 
9 Initial† F 2003 23 NS IV IV B Resection ABVD + it thiotepa PBRT (36 Gy) CR Alive (53.8+ mo) in CR 
10 Relapse M 2003 61 CHL NOS IV IE Resection BVAM, BEAM + PBSCT + it MTX None CR Dead in CR (58.8 mo) 
11 Relapse§ F 2004 41 CHL NOS IV IE Biopsy ifosfamide WBRT (36 Gy) CR Alive (35.5 mo) in CR 
12 Relapse§ M 1998 70 NS III IE Biopsy None Radiosurgery PR Dead from systemic PD (23.3 mo) 
13 Relapse† F 1988 29 NS II IE Biopsy MOPP WBRT (45 Gy) CR Alive (273+ mo) in CR 
19 Relapse§ M 2005 32 CHL NOS III IE Biopsy rituximab, IVAC, high-dose methotrexate None CR Dead from systemic PD (27.8 mo) 
14 Relapse M 2000 65 NS Unknown IV Resection None WBRT (10.8 Gy with 23.4 Gy boost) CR Dead in CR (235.3 mo) 
15 Relapse F 1986 29 NS II IV B Autopsy lomustine, procarbazine, prednisone, cytoxan + it cytarabine None PD Dead from PE with systemic and CNS PD (60.9 mo) 
16 Relapse† M 2004 59 MC IV IV B Biopsy Bonner Protocol None CR Dead from systemic PD (18.4 mo) 
Timing of CNS-HL diagnosis*SexYear of CNS-HL DiagnosisAge at CNS-HL diagnosis, yType of HLStage at first HL diagnosisStage at CNS-HL diagnosisConfirmation of CNS-HL diagnosisChemotherapy for CNS-HLRadiation for CNS-HL (dose)Response to first-line CNS treatmentStatus at last follow-up (survival since HL diagnosis)
1 Primary‡ F 2000 58 CHL NOS IE IE Resection None WBRT (35 Gy) CR Alive (90.3+ mo) in CR 
2 Primary‡ F 2008 60 NS IE IE Resection None WBRT (to begin) NA Alive (1+ mo) 
3 Initial§ M 2004 46 CHL NOS IE IE Biopsy Unknown Unknown Unknown Alive (2.1+ mo) 
4 Initial†§ M 2007 72 CHL NOS IE IE Resection None (surgery alone) None (surgery alone) NA Alive (5.4+ mo) in CR 
5 Initial§ F 1980 37 MC IE IE B Biopsy MVPP WBRT PR Dead from systemic PD (15.5 mo) 
6 Initial† M 1997 19 NS IV IV Biopsy Stamford V + PBSCT + it MTX PBRT (36 Gy) CR Alive (128.5+ mo) in CR 
7 Initial† M 2007 44 CHL NOS IV IV CSF ABVD Radiosurgery PR Dead from CNS PD (4.5 mo) 
9 Initial† F 2003 23 NS IV IV B Resection ABVD + it thiotepa PBRT (36 Gy) CR Alive (53.8+ mo) in CR 
10 Relapse M 2003 61 CHL NOS IV IE Resection BVAM, BEAM + PBSCT + it MTX None CR Dead in CR (58.8 mo) 
11 Relapse§ F 2004 41 CHL NOS IV IE Biopsy ifosfamide WBRT (36 Gy) CR Alive (35.5 mo) in CR 
12 Relapse§ M 1998 70 NS III IE Biopsy None Radiosurgery PR Dead from systemic PD (23.3 mo) 
13 Relapse† F 1988 29 NS II IE Biopsy MOPP WBRT (45 Gy) CR Alive (273+ mo) in CR 
19 Relapse§ M 2005 32 CHL NOS III IE Biopsy rituximab, IVAC, high-dose methotrexate None CR Dead from systemic PD (27.8 mo) 
14 Relapse M 2000 65 NS Unknown IV Resection None WBRT (10.8 Gy with 23.4 Gy boost) CR Dead in CR (235.3 mo) 
15 Relapse F 1986 29 NS II IV B Autopsy lomustine, procarbazine, prednisone, cytoxan + it cytarabine None PD Dead from PE with systemic and CNS PD (60.9 mo) 
16 Relapse† M 2004 59 MC IV IV B Biopsy Bonner Protocol None CR Dead from systemic PD (18.4 mo) 

CHL-NOS indicates classical Hodgkin's lymphoma not otherwise specified; MC, mixed cellularity; NS, nodular sclerosis; IE, isolated brain disease (“Initial” patients subsequently developed systemic HL, “Relapse” patients had no evidence of systemic disease when the brain relapse was discovered); it, intrathecal; PBSCT, peripheral blood stem cell transplantation; PBRT, partial brain radiation therapy; WBRT, whole brain radiation therapy; PE, pulmonary embolism; CR, complete response; PR, partial response; PD, progressive disease; MVPP, mustine, vinblastine, procarbazine, prednisone; BVAM, carmustine, vincristine, cytarabine, and methotrexate; BEAM, carmustine, etoposide, cytarabine, and melphalan; IVAC, ifosfamide, etoposide, and high-dose cytarabine; MOPP, mechlorethamine, vincristine, procarbazine, prednisone; CEP, lomustine, etoposide, prednisone; and Bonner Protocol, methotrexate, vincristine, ifosfamide, dexamethasone, procarbazine, vindesine, and cytarabine

*

Initial indicates CNS disease diagnosed prior to or concomitantly with systemic disease.

†

Dural based disease.

‡

No evidence of systemic HL.

§

Had immune dysregulation.

Staging determined by Cotswolds Staging Classification.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal